Edition:
Deutschland

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

56.96EUR
14 Aug 2020
Change (% chg)

€-0.66 (-1.15%)
Prev Close
€57.62
Open
€57.31
Day's High
€57.53
Day's Low
€56.56
Volume
2,180,232
Avg. Vol
3,703,500
52-wk High
€78.34
52-wk Low
€44.85

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Buy/Sell

Sell Hold Buy
1.96 Mean rating from 28 analysts

Overall

Beta: 1.09
Market Cap(Mil.): €56,607.28
Shares Outstanding(Mil.): 982.42
Dividend: 2.80
Yield (%): 4.92

Deals of the day-Mergers and acquisitions

Aug 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: ** British life insurer Prudential said it planned to spin off its U.S. business Jackson to focus on Africa and its largest market Asia, responding to investor pressure for a split.

Photo

Bayer takes on Astellas in purchase of experimental menopause relief

FRANKFURT Bayer moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas .

Photo

Bayer takes on Astellas in purchase of experimental menopause relief

FRANKFURT Bayer moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas .

UPDATE 2-Bayer takes on Astellas in purchase of experimental menopause relief

* Gynaecology unit suffered from litigation, generic competition (Releads, adds rival project, M&A strategy)

Bayer buys British developer of treatment for menopausal symptoms

FRANKFURT, Aug 11 Bayer agreed to acquire British biotech firm KaNDy Therapeutics Ltd. for an initial $425 million to strengthen its women's healthcare business with a prospective non-hormonal treatment of menopausal symptoms.

Regeneron profit beats, expects early results from COVID-19 trials in September

Regeneron Pharmaceuticals Inc beat second-quarter profit estimates on Wednesday, helped by higher sales of its eczema drug Dupixent and said it expects initial data from ongoing trials of its COVID-19 antibody cocktail next month.

UPDATE 2-Regeneron profit beats, expects early results from COVID-19 trials in September

Aug 5 Regeneron Pharmaceuticals Inc beat second-quarter profit estimates on Wednesday, helped by higher sales of its eczema drug Dupixent and said it expects initial data from ongoing trials of its COVID-19 antibody cocktail next month.

GLOBAL MARKETS-Asia shares poised to open lower, gold at fresh record

WASHINGTON, Aug 4 Asia shares were set to open lower on Wednesday, following a choppy trading session on Wall Street and losses in Europe.

GLOBAL MARKETS-Gold soars past $2,000, gold up on stimulus plan

NEW YORK, Aug 4 Gold surged past the $2,000 mark on Tuesday after Democrats and the White House appeared closer to agreement on new stimulus to help the coronavirus-hit economy while stocks on Wall Street ended higher as investors awaited more aid from Washington.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.32%
Rohstoffe -0.07%
Industrie -0.11%
Konjunktur abhängige Waren & Dienstleistungen -0.09%
Konjunktur unabhängige Waren & Dienstleistungen +0.04%
Finanzindustrie -0.32%
Pharma -0.19%
Technologie +0.19%
Telekommunikation -0.84%